Abstract
AIM: To study the clinical effect of valsartan on chronic type B hepatitis and liver cirrhosis.
METHODS: A total of 54 patients with chronic type B hepatitis and liver cirrhosis were divided into therapy group and control group, and each group had 27 cases. The patients in the control group were treated with routine treatment, and those in the therapy group, besides routine treatment, were added with valsartan 80 mg/day, and the therapeutic period was one month. Before and after treatment, serum HA, LN, PCIII, IV-C were measured by radio-immunoassay in each group. The parameters of ALT, AST, TBIL, Alb, r-GT and AKP were obtained. In the therapy group, five patients' liver tissues were obtained by liver biopsy, and then stained by H-E staining before and after treatment.
RESULTS: In these two groups, the parameters of ALT, AST, r-GT, AKP , TBIL, HA, and IV-C were all improved remarkably (P < 0.05 or 0.01) after treatment. In the therapy group, the parameters of ALT (5.7±1.9 ukat/L vs 1.3±0.7 ukat/L), AST (5.1±1.9 ukat/L vs 1.5±0.7 ukat/L), HA (298±107 ug/L vs 159±92 ug/L) and IV-C (102±24 ug/L vs 63±19 ug/L) were all descended (P < 0.05 or 0.01, 2.241≤t≤3.249) before and after treated with valsartan. Compared with control group, especially in chronic hepatitis patients, these parameters were decreased significantly (P < 0.05 or 0.01, 2.324 ≤ t ≤ 3.012), the liver microcirculation was improved, the inflammatory infiltration in liver was relieved, the liver tissue fibrosis was degraded, and the liver histology was remarkably improved.
CONCLUSION: As valsartan can effectively protect the liver cells, reverse the process of liver fibrosis, it is a feasible choice in the treatment of chronic hepatitis and liver cirrhosis.
Collapse